<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>17266886</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Segovia Cubero, Javier</dc:author>
<dc:author>Gómez Bueno, Manuel</dc:author>
<dc:author>Moñivas Palomero, Vanessa</dc:author>
<dc:author>Ortiz Uribe, Juan Camilo</dc:author>
<dc:author>González González, Magdalena</dc:author>
<dc:author>Alonso-Pulpón Rivera, Luis</dc:author>
<dc:description xml:lang="en">BACKGROUND AND OBJECTIVE Chronic thromboembolic pulmonary hypertension (CTEPH) has a dismal prognosis when there are no central pulmonary thrombi amenable to surgical thromboendarterectomy. Pulmonary vasodilators could be useful in this setting. Initial experience with bosentan in a small group of patients with CTEPH has shown favourable results on the short term (3 to 6 months), but long-term effects remain unknown. PATIENTS AND METHOD We retrospectively describe the effects of bosentan in 6 CTEPH patients with a mean follow-up period of 15 months (range, 8-26). RESULTS At 3-month follow-up, all patients had experienced clinical improvement, with a statistical trend towards reduced pulmonary vascular resistance [1,008 (624) dyn/sec/cm-5 versus 768 (392), p = 0.07]. Clinical improvement persisted on the long-term, [baseline NYHA functional class 3.0 (0.4) versus 2.0 (0) at the last follow-up visit, p &lt; 0.01]. Six-minute walk-test results [baseline 230 (124) meters versus a 313 (70) at 1 year] and NTproBNP [2,225 (2,079) pg/ml versus a 1,056 (1,104) at 1 year] were also consistent with persistent beneficial effect. CONCLUSIONS Bosentan seemed to provide long-term benefits in this small series of patients with CTEPH.</dc:description>
<dc:type>Clinical Trial</dc:type>
<dc:language>es</dc:language>
<dc:date>2007 Jan 13 </dc:date>
<dc:title xml:lang="es">Efectividad del bosentán en el tratamiento de la hipertensión pulmonar debida a tromboembolia venosa crónica.</dc:title>
<dc:title xml:lang="en">[Role of bosentan in patients with chronic venous thromboembolic pulmonary hypertension].</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
